Cellectar Biosciences, Inc. Gains 28.71%
Wed, Dec 02, 2020 at 05:32 PM
Cellectar Biosciences, Inc. (CLRB:NASDAQ) soared at $1.95, representing a gain of 28.7%. On Tue 01 Dec 20, CLRB:NASDAQ hit a New 2-Week High of $1.52. The stock appeared on our News Catalysts scanner on Fri 27 Nov 20 at 07:25 PM in the 'ACQUISITION' category. From Tue 17 Nov 20, the stock recorded 77.78% Up Days and 70.00% Green Days
About Cellectar Biosciences, Inc. (CLRB:NASDAQ)
Cellectar Biosciences Inc is a biopharmaceutical company. It is engaged in developing compounds for treatment and imaging of cancer. Its portfolio consists of PET imaging agents, optical imaging agents, and therapeutic agents.
Top 10 Gainers:
- Merrimack Pharmaceuticals, Inc. (MACK:NASDAQ), 59.07%
- Tredegar Corporation (TG:NYSE), 29.86%
- Kingsway Financial Services Inc. (KFS:NYSE), 28.71%
- Cellectar Biosciences, Inc. (CLRB:NASDAQ), 28.71%
- Catabasis Pharmaceuticals, Inc. (CATB:NASDAQ), 28.22%
- FSTX (FSTX:NASDAQ), 27.63%
- Acorda Therapeutics, Inc. (ACOR:NASDAQ), 26.7%
- Sequential Brands Group, Inc. (SQBG:NASDAQ), 25.16%
- Natuzzi S.p.A. (NTZ:NYSE), 24.59%
- Sundial Growers Inc. (SNDL:NASDAQ), 23.83%